In Moldova, insulin and other diabetes medicines, such as Metformin, Sulfonylureas, and Meglitinide, are provided free of charge for people living with diabetes (PwD). Other medications like DPP4 and SGLT2 inhibitors are reimbursed at 75% and 65% of their cost by the National Health Insurance (NHI).
While syringes and needles for insulin administration are covered by the NHI, they only meet about two-thirds of the actual needs of PwD. Newer technologies like continuous glucose monitors and insulin pumps are limited to children, with approximately 100 children living with diabetes having access to insulin pumps.
Over the past 20 years, Moldova has implemented four National Programmes for Diabetes Prevention. The most recent programme is in its final stages and includes measures for screening diabetes and its complications, diabetes education and PwD engagement.
This country profile was developed with the help of the Society of Endocrinologists of the Republic of Moldova